Metropolitan Life Insurance CO Crinetics Pharmaceuticals, Inc. Transaction History

Metropolitan Life Insurance CO

$253 Million
Q2 2024

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$34.76 - $46.81 $6,326 - $8,519	-182 Reduced 4.85%	3,573 $167,000
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $14,468 - $27,714	906 Added 31.8%	3,755 $111,000
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $5,236 - $7,216	-342 Reduced 10.72%	2,849 $45,000
Q4 2022 Jun 14, 2023	BUY	$15.49 - $19.05 $5,297 - $6,515	342 Added 12.0%	3,191 $58.4 Million
Q3 2022 Jun 14, 2023	BUY	$18.11 - $22.37 $6,193 - $7,650	342 Added 12.0%	3,191 $62.7 Million
Q2 2022 Jun 20, 2023	BUY	$16.49 - $27.64 $5,639 - $9,452	342 Added 12.0%	3,191 $59,000
Q2 2022 Mar 30, 2023	BUY	$16.49 - $27.64 $7,074 - $11,857	429 Added 15.53%	3,191 $59,000
Q2 2022 Aug 11, 2022	BUY	$16.49 - $27.64 $7,074 - $11,857	429 Added 15.53%	3,191 $60,000
Q1 2022 Jun 20, 2023	SELL	$17.15 - $28.31 $1,492 - $2,462	-87 Reduced 3.05%	2,762 $60,000
Q1 2022 Mar 30, 2023	SELL	$17.15 - $28.31 $155,430 - $256,573	-9,063 Reduced 76.64%	2,762 $60,000
Q1 2022 May 12, 2022	SELL	$17.15 - $28.31 $155,430 - $256,573	-9,063 Reduced 76.64%	2,762 $61,000
Q4 2021 Jun 21, 2023	BUY	$19.35 - $28.41 $173,685 - $255,008	8,976 Added 315.06%	11,825 $335,000
Q4 2021 Mar 30, 2023	BUY	$19.35 - $28.41 $41,892 - $61,507	2,165 Added 22.41%	11,825 $335,000
Q4 2021 Feb 15, 2022	BUY	$19.35 - $28.41 $41,892 - $61,507	2,165 Added 22.41%	11,825 $336,000
Q3 2021 Jun 21, 2023	BUY	$16.88 - $25.23 $114,969 - $171,841	6,811 Added 239.07%	9,660 $203,000
Q2 2021 Jun 21, 2023	BUY	$15.9 - $21.15 $108,294 - $144,052	6,811 Added 239.07%	9,660 $182,000
Q2 2021 Mar 30, 2023	BUY	$15.9 - $21.15 $31,386 - $41,750	1,974 Added 25.68%	9,660 $182,000
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $153,466 - $204,139	9,652 Added 120650.0%	9,660 $182,000
Q1 2021 Jun 26, 2023	BUY	$13.3 - $17.55 $64,332 - $84,889	4,837 Added 169.78%	7,686 $117 Million
Q1 2021 Mar 30, 2023	SELL	$13.3 - $17.55 $14,709 - $19,410	-1,106 Reduced 12.58%	7,686 $117,000
Q1 2021 May 14, 2021	SELL	$13.3 - $17.55 $116,827 - $154,159	-8,784 Reduced 99.91%	8 $117,000
Q4 2020 Jun 22, 2023	BUY	$12.08 - $17.46 $71,791 - $103,764	5,943 Added 208.6%	8,792 $124,000
Q3 2020 Jun 26, 2023	BUY	$13.62 - $17.66 $80,943 - $104,953	5,943 Added 208.6%	8,792 $137,000
Q2 2020 Jun 26, 2023	BUY	$13.04 - $23.23 $77,496 - $138,055	5,943 Added 208.6%	8,792 $154,000
Q2 2020 Mar 30, 2023	BUY	$13.04 - $23.23 $60,231 - $107,299	4,619 Added 110.69%	8,792 $154,000
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $60,231 - $107,299	4,619 Added 110.69%	8,792 $154,000
Q1 2020 Jul 12, 2023	BUY	$11.52 - $26.46 $15,252 - $35,033	1,324 Added 46.47%	4,173 $61,000
Q4 2019 Jul 12, 2023	BUY	$15.24 - $25.09 $20,177 - $33,219	1,324 Added 46.47%	4,173 $104,000
Q4 2019 Mar 30, 2023	BUY	$15.24 - $25.09 $14,965 - $24,638	982 Added 30.77%	4,173 $104,000
Q4 2019 Feb 14, 2020	BUY	$15.24 - $25.09 $63,596 - $104,700	4,173 New	4,173 $105,000
Q2 2019 Jul 12, 2023	SELL	$21.48 - $27.71 $41,327 - $53,314	-1,924 Reduced 67.53%	925 $23.1 Million

Others Institutions Holding CRNX

# of Institutions

244

Shares Held

78.2M

Call Options Held

268K

Put Options Held

197K

Black Rock Inc. New York, NY

6.23M
Shares

$316 Million
0.01% of portfolio
Driehaus Capital Management LLC Chicago, IL

6.11M
Shares

$310 Million
2.95% of portfolio
Wellington Management Group LLP Boston, MA

4.62M
Shares

$234 Million
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

4.51M
Shares

$229 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.41M
Shares

$224 Million
0.02% of portfolio

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.73B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account